Business Description
Innovent Biologics Inc
ISIN : US45783L1017
Share Class Description:
IVBIY: ADRCompare
Compare
Traded in other countries / regions
01801.Hong KongIVBXF.USA6IB.Germany IPO Date
2019-04-18Description
Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has eight commercialized oncology products and two commercialized non-oncology products as of August 2023. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.52 | |||||
| Equity-to-Asset | 0.61 | |||||
| Debt-to-Equity | 0.27 | |||||
| Debt-to-EBITDA | -4.14 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 3.9 | |||||
| Beneish M-Score | -2.26 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 9 | |||||
| 3-Year EBITDA Growth Rate | 9.1 | |||||
| 3-Year EPS without NRI Growth Rate | 6.2 | |||||
| 3-Year FCF Growth Rate | 2.8 | |||||
| 3-Year Book Growth Rate | 4.4 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 28.91 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 9-Day RSI | 0.05 | |||||
| 14-Day RSI | 0.68 | |||||
| 6-1 Month Momentum % | 12.94 | |||||
| 12-1 Month Momentum % | 5.31 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.68 | |||||
| Quick Ratio | 2.51 | |||||
| Cash Ratio | 2.04 | |||||
| Days Inventory | 276.18 | |||||
| Days Sales Outstanding | 55.43 | |||||
| Days Payable | 75.53 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5 | |||||
| Shareholder Yield % | -4.01 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 82.44 | |||||
| Operating Margin % | -10.63 | |||||
| Net Margin % | -17.25 | |||||
| FCF Margin % | -12.92 | |||||
| ROE % | -10.76 | |||||
| ROA % | -6.54 | |||||
| ROIC % | -7.41 | |||||
| 3-Year ROIIC % | -11.31 | |||||
| ROC (Joel Greenblatt) % | -23.11 | |||||
| ROCE % | -7.57 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 335.96 | |||||
| PS Ratio | 7.75 | |||||
| PB Ratio | 4.76 | |||||
| Price-to-Tangible-Book | 5.18 | |||||
| Price-to-Operating-Cash-Flow | 100.51 | |||||
| EV-to-EBIT | -43.14 | |||||
| EV-to-Forward-EBIT | 549.79 | |||||
| EV-to-EBITDA | -64.44 | |||||
| EV-to-Forward-EBITDA | 80.17 | |||||
| EV-to-Revenue | 6.94 | |||||
| EV-to-Forward-Revenue | 5.41 | |||||
| EV-to-FCF | -53.67 | |||||
| Price-to-GF-Value | 0.66 | |||||
| Price-to-Net-Current-Asset-Value | 18.59 | |||||
| Price-to-Net-Cash | 106.39 | |||||
| Earnings Yield (Greenblatt) % | -2.32 | |||||
| FCF Yield % | -1.64 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:IVBIY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Innovent Biologics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1,035.608 | ||
| EPS (TTM) ($) | -0.451 | ||
| Beta | 0.49 | ||
| 3-Year Sharpe Ratio | 0.39 | ||
| 3-Year Sortino Ratio | 1.02 | ||
| Volatility % | 32.26 | ||
| 14-Day RSI | 0.68 | ||
| 14-Day ATR ($) | 0.084234 | ||
| 20-Day SMA ($) | 20.1475 | ||
| 12-1 Month Momentum % | 5.31 | ||
| 52-Week Range ($) | 18.66 - 24.14 | ||
| Shares Outstanding (Mil) | 407.1 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Innovent Biologics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Innovent Biologics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Innovent Biologics Inc Frequently Asked Questions
What is Innovent Biologics Inc(IVBIY)'s stock price today?
The current price of IVBIY is $19.15. The 52 week high of IVBIY is $24.14 and 52 week low is $18.66.
When is next earnings date of Innovent Biologics Inc(IVBIY)?
The next earnings date of Innovent Biologics Inc(IVBIY) is 2025-03-20 Est..
Does Innovent Biologics Inc(IVBIY) pay dividends? If so, how much?
Innovent Biologics Inc(IVBIY) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers